Addressing the challenge of type 2 diabetes

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1248, 2000-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond Low-Density Lipoprotein: Addressing the Atherogenic Lipid Triad in Type 2 Diabetes Mellitus and the Metabolic Syndrome

By Nesto Richard W.

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 6, 2005-01 ,pp. : 379-387

Adis International

Access to resources Recommend Favorite

Dapagliflozin for the treatment of type 2 diabetes

By Abdul-Ghani Muhammad A DeFronzo Ralph A

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1695-1703

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin: In Type 2 Diabetes Mellitus

By Scott Lesley J.

Drugs, Vol. 71, Iss. 5, 2011-03 ,pp. : 611-624

Adis International

Access to resources Recommend Favorite

Metformin ++ saxagliptin for type 2 diabetes

By Scheen André J

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 139-146

Informa Healthcare

Access to resources Recommend Favorite

Thiazolidinediones in the treatment of Type 2 diabetes

By Greenberg Andrew S Pittas Anastassios G

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 529-540

Informa Healthcare

Access to resources Recommend Favorite